Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.
Analyst Recommendations
This is a summary of current ratings and target prices for Dianthus Therapeutics and Connect Biopharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dianthus Therapeutics | 1 | 0 | 13 | 1 | 2.93 |
| Connect Biopharma | 1 | 0 | 8 | 0 | 2.78 |
Dianthus Therapeutics presently has a consensus target price of $129.83, suggesting a potential upside of 69.10%. Connect Biopharma has a consensus target price of $5.88, suggesting a potential upside of 666.47%. Given Connect Biopharma’s higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Dianthus Therapeutics.
Risk & Volatility
Dianthus Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500.
Earnings & Valuation
This table compares Dianthus Therapeutics and Connect Biopharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dianthus Therapeutics | $1.90 million | 2,209.76 | -$162.34 million | ($4.15) | -18.50 |
| Connect Biopharma | $60,000.00 | 804.44 | -$55.48 million | ($1.19) | -0.64 |
Connect Biopharma has lower revenue, but higher earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Dianthus Therapeutics and Connect Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dianthus Therapeutics | -10,096.95% | -22.53% | -21.55% |
| Connect Biopharma | N/A | -165.41% | -121.58% |
Insider & Institutional Ownership
47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Dianthus Therapeutics beats Connect Biopharma on 8 of the 15 factors compared between the two stocks.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
